Elucidation of Anti-Inflammatory Constituents in Hypericum
Total Page:16
File Type:pdf, Size:1020Kb
Load more
Recommended publications
-
PRODUCT INFORMATION Mefenamic Acid Item No
PRODUCT INFORMATION Mefenamic Acid Item No. 23650 CAS Registry No.: 61-68-7 OH Formal Name: 2-[(2,3-dimethylphenyl)amino]-benzoic acid O Synonyms: C.I. 473, CN 35355, NSC 94437 H C H NO MF: 15 15 2 N FW: 241.3 Purity: ≥98% Supplied as: A solid Storage: 4°C Stability: ≥1 year Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis. Laboratory Procedures Mefenamic acid is supplied as a solid. A stock solution may be made by dissolving the mefenamic acid in the solvent of choice, which should be purged with an inert gas. Mefenamic acid is slightly soluble in DMSO and methanol. Description Mefenamic acid is a non-steroidal anti-inflammatory drug (NSAID) and a COX-2 inhibitor.1 It binds to COX-2 (Kd = 4 nM) and inhibits COX-2-dependent oxygenation of arachidonic acid (Item Nos. 90010 | 90010.1 | 10006607) in vitro (Ki = 10 µM). Mefenamic acid (30 mg/kg) reduces acetic acid-induced writhing in rats.2 It inhibits increases in skin thickness in a mouse model of delayed-type hypersensitivity induced by dinitrochlorobenzene (DNBC).2 Mefenamic acid also reduces the antibody response to sheep red blood cells in mice. References 1. Prusakiewicz, J.J., Duggan, K.C., Rouzer, C.A., et al. Differential sensitivity and mechanism of inhibition of COX-2 oxygenation of arachidonic acid and 2-arachidonoylglycerol by ibuprofen and mefenamic acid. Biochemistry 48(31), 7353-7355 (2009). 2. Roszkowski, A.P., Rooks, W.H., Tomolonis, A.J., et al. Anti-inflammatory and analgetic properties of d-2-(6’-methoxy-2’-naphthyl)-propionic acid (naproxen). -
Hyperforin Inhibits Cell Growth by Inducing Intrinsic and Extrinsic
ANTICANCER RESEARCH 37 : 161-168 (2017) doi:10.21873/anticanres.11301 Hyperforin Inhibits Cell Growth by Inducing Intrinsic and Extrinsic Apoptotic Pathways in Hepatocellular Carcinoma Cells I-TSANG CHIANG 1,2,3* , WEI-TING CHEN 4* , CHIH-WEI TSENG 5, YEN-CHUNG CHEN 2,6 , YU-CHENG KUO 7, BI-JHIH CHEN 8, MAO-CHI WENG 9, HWAI-JENG LIN 10,11# and WEI-SHU WANG 2,12,13# Departments of 1Radiation Oncology, 6Pathology, and 13 Medicine, and 2Cancer Medical Care Center, National Yang-Ming University Hospital, Yilan, Taiwan, R.O.C.; 3Department of Radiological Technology, Central Taiwan University of Science and Technology, Taichung, Taiwan, R.O.C.; 4Department of Psychiatry, Zuoying Branch of Kaohsiung Armed Forces General Hospital, Kaohsiung, Taiwan, R.O.C.; 5Division of Gastroenterology, Department of Internal Medicine, Dalin Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation, Chia-Yi, Taiwan, R.O.C.; 7Radiation Oncology, Show Chwan Memorial Hospital, Changhua, Taiwan, R.O.C.; 8Department of Laboratory Medicine, Changhua Christian Hospital, Changhua Christian Medical Foundation, Changhua, Taiwan, R.O.C.; 9Institute of Nuclear Energy Research, Atomic Energy Council, Taoyuan, Taiwan, R.O.C.; 10 Department of Internal Medicine, Division of Gastroenterology and Hepatology, College of Medicine, School of Medicine, Taipei Medical University, Taipei, Taiwan, R.O.C.; 11 Department of Internal Medicine, Division of Gastroenterology and Hepatology, Shuang-Ho Hospital, New Taipei, Taiwan, R.O.C.; 12 National Yang-Ming University School of Medicine, Taipei, Taiwan, R.O.C. Abstract. The aim of the present study was to investigate the (c-FLIP), X-linked inhibitor of apoptosis protein (XIAP), antitumor effect and mechanism of action of hyperforin in myeloid cell leukemia 1(MCL1), and cyclin-D1] were hepatocellular carcinoma (HCC) SK-Hep1 cells in vitro. -
N-Acyl-Dopamines: Novel Synthetic CB1 Cannabinoid-Receptor Ligands
Biochem. J. (2000) 351, 817–824 (Printed in Great Britain) 817 N-acyl-dopamines: novel synthetic CB1 cannabinoid-receptor ligands and inhibitors of anandamide inactivation with cannabimimetic activity in vitro and in vivo Tiziana BISOGNO*, Dominique MELCK*, Mikhail Yu. BOBROV†, Natalia M. GRETSKAYA†, Vladimir V. BEZUGLOV†, Luciano DE PETROCELLIS‡ and Vincenzo DI MARZO*1 *Istituto per la Chimica di Molecole di Interesse Biologico, C.N.R., Via Toiano 6, 80072 Arco Felice, Napoli, Italy, †Shemyakin-Ovchinnikov Institute of Bioorganic Chemistry, R. A. S., 16/10 Miklukho-Maklaya Str., 117871 Moscow GSP7, Russia, and ‡Istituto di Cibernetica, C.N.R., Via Toiano 6, 80072 Arco Felice, Napoli, Italy We reported previously that synthetic amides of polyunsaturated selectivity for the anandamide transporter over FAAH. AA-DA fatty acids with bioactive amines can result in substances that (0.1–10 µM) did not displace D1 and D2 dopamine-receptor interact with proteins of the endogenous cannabinoid system high-affinity ligands from rat brain membranes, thus suggesting (ECS). Here we synthesized a series of N-acyl-dopamines that this compound has little affinity for these receptors. AA-DA (NADAs) and studied their effects on the anandamide membrane was more potent and efficacious than anandamide as a CB" transporter, the anandamide amidohydrolase (fatty acid amide agonist, as assessed by measuring the stimulatory effect on intra- hydrolase, FAAH) and the two cannabinoid receptor subtypes, cellular Ca#+ mobilization in undifferentiated N18TG2 neuro- CB" and CB#. NADAs competitively inhibited FAAH from blastoma cells. This effect of AA-DA was counteracted by the l µ N18TG2 cells (IC&! 19–100 M), as well as the binding of the CB" antagonist SR141716A. -
PRE Evaluation Report for Hypericum X Inodorum 'Kolmapuki' PUMPKIN
PRE Evaluation Report -- Hypericum x inodorum 'Kolmapuki' PUMPKIN Plant Risk Evaluator -- PRE™ Evaluation Report Hypericum x inodorum 'Kolmapuki' PUMPKIN -- Illinois 2017 Farm Bill PRE Project PRE Score: 14 -- Evaluate this plant further Confidence: 57 / 100 Questions answered: 20 of 20 -- Valid (80% or more questions answered) Privacy: Public Status: Submitted Evaluation Date: September 16, 2017 This PDF was created on June 15, 2018 Page 1/19 PRE Evaluation Report -- Hypericum x inodorum 'Kolmapuki' PUMPKIN Plant Evaluated Hypericum x inodorum 'Kolmapuki' PUMPKIN Image by Dobbie Garden Centres Page 2/19 PRE Evaluation Report -- Hypericum x inodorum 'Kolmapuki' PUMPKIN Evaluation Overview A PRE™ screener conducted a literature review for this plant (Hypericum x inodorum 'Kolmapuki' PUMPKIN) in an effort to understand the invasive history, reproductive strategies, and the impact, if any, on the region's native plants and animals. This research reflects the data available at the time this evaluation was conducted. Summary The attractive fruits of Hypericum x inodorum contain copious seeds which germinate easily, and this constitutes the primary risk of invasion in Illinois. There is no evidence of vegetative reproduction. This hybrid is not naturalized or invasive in a climate similar to Illinois and neither are its parent species, H. androsaemum and H. hircinum. Cold hardiness may be a limiting factor in Illinois. Information on dispersal and impacts are borrowed from the literature on H. androsaemum in Australia, where it and H. x inodorum are declared noxious weeds. Confidence levels are lowered for those answers, which seem somewhat speculative, but important to consider nonetheless. General Information Status: Submitted Screener: Emily Russell Evaluation Date: September 16, 2017 Plant Information Plant: Hypericum x inodorum 'Kolmapuki' PUMPKIN If the plant is a cultivar, how does its behavior differs from its parent's? Hypericum x inodorum is a hybrid between H. -
WO 2013/142184 Al 26 September 2013 (26.09.2013) P O P C T
(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (10) International Publication Number (43) International Publication Date WO 2013/142184 Al 26 September 2013 (26.09.2013) P O P C T (51) International Patent Classification: DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, A61K 33/16 (2006.01) A61K 31/7048 (2006.01) HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, A61K 33/14 (2006.01) A61K 31/70 (2006.01) KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, A61K 33/18 (2006.01) A61K 31/4196 (2006.01) ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, (21) International Application Number: RW, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, PCT/US20 13/030788 TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, (22) International Filing Date: ZM, ZW. 13 March 2013 (13.03.2013) (84) Designated States (unless otherwise indicated, for every (25) Filing Language: English kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, (26) Publication Language: English UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, (30) Priority Data: TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, 61/612,689 19 March 2012 (19.03.2012) US EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, (71) Applicant: YALE UNIVERSITY [US/US]; Two Whitney TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, Avenue, New Haven, CT 065 10 (US). -
Role of Arachidonic Acid and Its Metabolites in the Biological and Clinical Manifestations of Idiopathic Nephrotic Syndrome
International Journal of Molecular Sciences Review Role of Arachidonic Acid and Its Metabolites in the Biological and Clinical Manifestations of Idiopathic Nephrotic Syndrome Stefano Turolo 1,* , Alberto Edefonti 1 , Alessandra Mazzocchi 2, Marie Louise Syren 2, William Morello 1, Carlo Agostoni 2,3 and Giovanni Montini 1,2 1 Fondazione IRCCS Ca’ Granda-Ospedale Maggiore Policlinico, Pediatric Nephrology, Dialysis and Transplant Unit, Via della Commenda 9, 20122 Milan, Italy; [email protected] (A.E.); [email protected] (W.M.); [email protected] (G.M.) 2 Department of Clinical Sciences and Community Health, University of Milan, 20122 Milan, Italy; [email protected] (A.M.); [email protected] (M.L.S.); [email protected] (C.A.) 3 Fondazione IRCCS Ca’ Granda Ospedale Maggiore Policlinico, Pediatric Intermediate Care Unit, 20122 Milan, Italy * Correspondence: [email protected] Abstract: Studies concerning the role of arachidonic acid (AA) and its metabolites in kidney disease are scarce, and this applies in particular to idiopathic nephrotic syndrome (INS). INS is one of the most frequent glomerular diseases in childhood; it is characterized by T-lymphocyte dysfunction, alterations of pro- and anti-coagulant factor levels, and increased platelet count and aggregation, leading to thrombophilia. AA and its metabolites are involved in several biological processes. Herein, Citation: Turolo, S.; Edefonti, A.; we describe the main fields where they may play a significant role, particularly as it pertains to their Mazzocchi, A.; Syren, M.L.; effects on the kidney and the mechanisms underlying INS. AA and its metabolites influence cell Morello, W.; Agostoni, C.; Montini, G. -
St. John's Wort 2018
ONLINE SERIES MONOGRAPHS The Scientific Foundation for Herbal Medicinal Products Hyperici herba St. John's Wort 2018 www.escop.com The Scientific Foundation for Herbal Medicinal Products HYPERICI HERBA St. John's Wort 2018 ESCOP Monographs were first published in loose-leaf form progressively from 1996 to 1999 as Fascicules 1-6, each of 10 monographs © ESCOP 1996, 1997, 1999 Second Edition, completely revised and expanded © ESCOP 2003 Second Edition, Supplement 2009 © ESCOP 2009 ONLINE SERIES ISBN 978-1-901964-61-5 Hyperici herba - St. John's Wort © ESCOP 2018 Published by the European Scientific Cooperative on Phytotherapy (ESCOP) Notaries House, Chapel Street, Exeter EX1 1EZ, United Kingdom www.escop.com All rights reserved Except for the purposes of private study, research, criticism or review no part of this text may be reproduced, stored in a retrieval system or transmitted, in any form or by any means, without the written permission of the publisher. Important Note: Medical knowledge is ever-changing. As new research and clinical experience broaden our knowledge, changes in treatment may be required. In their efforts to provide information on the efficacy and safety of herbal drugs and herbal preparations, presented as a substantial overview together with summaries of relevant data, the authors of the material herein have consulted comprehensive sources believed to be reliable. However, in view of the possibility of human error by the authors or publisher of the work herein, or changes in medical knowledge, neither the authors nor the publisher, nor any other party involved in the preparation of this work, warrants that the information contained herein is in every respect accurate or complete, and they are not responsible for any errors or omissions or for results obtained by the use of such information. -
THE L5178Y SUBLINES: a SUMMARY of 40 YEAR STUDIES in WARSAW Irena Szumiel
ISSN 1425-7351 PL0601824 RAPORTY IChTJ. SERIA B nr 2/2005 THE L5178Y SUBLINES: A SUMMARY OF 40 YEAR STUDIES IN WARSAW Irena Szumiel INSTYTUT CHEMII I TECHNIKI JĄDROWEJ INSTITUTE OF NUCLEAR CHEMISTRY AND TECHNOLOGY RAPORTY IChTJ. SERIA B nr 2/2005 THE L5178Y SUBLINES: A SUMMARY OF 40 YEAR STUDIES IN WARSAW Irena Szumiel Warszawa 2005 AUTHOR Irena Szumiel Department of Radiobiology and Health Protection, Institute of Nuclear Chemistry and Technology This report is an extended version of the paper: " 'The L5178Y sublines: a look back from 40 years. 1.General characteristics. 2. Response to ionising radiation", published in International Journal of Radiation Biology, vol. 81 (2005) by kind permission of Taylor & Francis (http://www. tandf.co.uk) ADDRESS OF THE EDITORIAL OFFICE Institute of Nuclear Chemistry and Technology Dorodna 16, 03-195 Warszawa, POLAND phone: (+4822) 811 06 56, fax: (+4822) 81115 32, e-mail: [email protected] Papers are published in the form as received from the Authors The L5178Y sublines: a summary of 40 year studies in Warsaw The purpose of this report has been to review and summarise the results of 40 year studies concerning the general characteristics and response to UVC radiation, hydrogen peroxide and ionising radiation of the pair of L5178Y (LY) sublines, LY-R and LY-S, that differ in sen- sitivity to various DNA damaging agents. Comparison of karyotypes shows a number of differences in the banding patterns. Differences are found in ion transport and the ganglioside pattern of the plasma membranes, as well as in the content and turnover rate of poly(ADP-ribose) polymers. -
Synaptic Action of Anandamide and Related Substances in Mammalian Brain
SYNAPTIC ACTION OF ANANDAMIDE AND RELATED SUBSTANCES IN MAMMALIAN BRAIN by Chengyong Liao M.Sc., Sichuan University, 1991 B.Sc., Sichuan University, 1984 THESIS SUBMITTED IN PARTIAL FULFILLMENT OF THE REQUIREMENTS FOR THE DEGREE OF DOCTOR OF PHILOSOPHY Inthe Department of Biological Sciences © Chengyong Liao 2007 SIMON FRASER UNIVERSITY 2007 All rights reserved. This work may not be reproduced in whole or in part, by photocopy or other means, without permission ofthe author. APPROVAL Name: Chengyong Liao Degree: Doctor of Philosophy Title of Thesis: Synaptic Actions of Anandamide and Related Substances in Mammalian Brain Examining Committee: Chair: Dr. Z. Punja Professor ofDepartment ofBiological Sciences, SFU. Dr. R. A. Nicholson Senior Supervisor Associate Professor ofDepartment ofBiological Sciences, SFU. Dr. C. J. Kennedy, Supervisor Associate Professor of Department ofBiological Sciences, SFU Dr. F. C. P. Law, Supervisor Professor ofDepartment ofBiological Sciences, SFU Dr. M. A. Silverman Public Examiner Associate Professor ofDepartment ofBiological Sciences, SFU Dr. J. Church External Examiner Professor ofDepartment ofCellular and Physiological Sciences, UBC Date Defended/Approved: 11 SIMON FRASER UNIVERSITY LIBRARY Declaration of Partial Copyright Licence The author, whose copyright is declared on the title page of this work, has granted to Simon Fraser University the right to lend this thesis, project or extended essay to users of the Simon Fraser University Library, and to make partial or single copies only for such users or -
Compositions and Methods for Selective Delivery of Oligonucleotide Molecules to Specific Neuron Types
(19) TZZ ¥Z_T (11) EP 2 380 595 A1 (12) EUROPEAN PATENT APPLICATION (43) Date of publication: (51) Int Cl.: 26.10.2011 Bulletin 2011/43 A61K 47/48 (2006.01) C12N 15/11 (2006.01) A61P 25/00 (2006.01) A61K 49/00 (2006.01) (2006.01) (21) Application number: 10382087.4 A61K 51/00 (22) Date of filing: 19.04.2010 (84) Designated Contracting States: • Alvarado Urbina, Gabriel AT BE BG CH CY CZ DE DK EE ES FI FR GB GR Nepean Ontario K2G 4Z1 (CA) HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL • Bortolozzi Biassoni, Analia Alejandra PT RO SE SI SK SM TR E-08036, Barcelona (ES) Designated Extension States: • Artigas Perez, Francesc AL BA ME RS E-08036, Barcelona (ES) • Vila Bover, Miquel (71) Applicant: Nlife Therapeutics S.L. 15006 La Coruna (ES) E-08035, Barcelona (ES) (72) Inventors: (74) Representative: ABG Patentes, S.L. • Montefeltro, Andrés Pablo Avenida de Burgos 16D E-08014, Barcelon (ES) Edificio Euromor 28036 Madrid (ES) (54) Compositions and methods for selective delivery of oligonucleotide molecules to specific neuron types (57) The invention provides a conjugate comprising nucleuc acid toi cell of interests and thus, for the treat- (i) a nucleic acid which is complementary to a target nu- ment of diseases which require a down-regulation of the cleic acid sequence and which expression prevents or protein encoded by the target nucleic acid as well as for reduces expression of the target nucleic acid and (ii) a the delivery of contrast agents to the cells for diagnostic selectivity agent which is capable of binding with high purposes. -
Note: the Letters 'F' and 'T' Following the Locators Refers to Figures and Tables
Index Note: The letters ‘f’ and ‘t’ following the locators refers to figures and tables cited in the text. A Acyl-lipid desaturas, 455 AA, see Arachidonic acid (AA) Adenophostin A, 71, 72t aa, see Amino acid (aa) Adenosine 5-diphosphoribose, 65, 789 AACOCF3, see Arachidonyl trifluoromethyl Adlea, 651 ketone (AACOCF3) ADP, 4t, 10, 155, 597, 598f, 599, 602, 669, α1A-adrenoceptor antagonist prazosin, 711t, 814–815, 890 553 ADPKD, see Autosomal dominant polycystic aa 723–928 fragment, 19 kidney disease (ADPKD) aa 839–873 fragment, 17, 19 ADPKD-causing mutations Aβ, see Amyloid β-peptide (Aβ) PKD1 ABC protein, see ATP-binding cassette protein L4224P, 17 (ABC transporter) R4227X, 17 Abeele, F. V., 715 TRPP2 Abbott Laboratories, 645 E837X, 17 ACA, see N-(p-amylcinnamoyl)anthranilic R742X, 17 acid (ACA) R807X, 17 Acetaldehyde, 68t, 69 R872X, 17 Acetic acid-induced nociceptive response, ADPR, see ADP-ribose (ADPR) 50 ADP-ribose (ADPR), 99, 112–113, 113f, Acetylcholine-secreting sympathetic neuron, 380–382, 464, 534–536, 535f, 179 537f, 538, 711t, 712–713, Acetylsalicylic acid, 49t, 55 717, 770, 784, 789, 816–820, Acrolein, 67t, 69, 867, 971–972 885 Acrosome reaction, 125, 130, 301, 325, β-Adrenergic agonists, 740 578, 881–882, 885, 888–889, α2 Adrenoreceptor, 49t, 55, 188 891–895 Adult polycystic kidney disease (ADPKD), Actinopterigy, 223 1023 Activation gate, 485–486 Aframomum daniellii (aframodial), 46t, 52 Leu681, amino acid residue, 485–486 Aframomum melegueta (Melegueta pepper), Tyr671, ion pathway, 486 45t, 51, 70 Acute myeloid leukaemia and myelodysplastic Agelenopsis aperta (American funnel web syndrome (AML/MDS), 949 spider), 48t, 54 Acylated phloroglucinol hyperforin, 71 Agonist-dependent vasorelaxation, 378 Acylation, 96 Ahern, G. -
Inhibitory Effects of Curcumin on in Vitro Lipoxygenase and Cyclooxygenase Activities in Mouse Epidermis1
[CANCER RESEARCH 51,813-819, February 1, 1991) Inhibitory Effects of Curcumin on in Vitro Lipoxygenase and Cyclooxygenase Activities in Mouse Epidermis1 Mou-Tuan Huang, Thomas Lysz, Thomas Ferrara, Tanveer F. Abidi, Jeffrey D. Laskin, and Allan H. Conney2 Laboratory for Cancer Research, Department of Chemical Biology and Pharmacognosy, College of Pharmacy, Rutgers, The State university of New Jersey, Piscataway, New Jersey 08855-0789 [M-T. H., T. F., A. H. C.J, Department of Surgery, VMDNJ-New Jersey Medical School, Newark, New Jersey 07103-2757 ¡T.L.J, and Department of Environmental and Community Medicine, UMDNJ-Robert Wood Johnson Medical School, Piscataway, New Jersey 08854 fT. F.A.,J.D. L.] ABSTRACT been reported to possess both antioxidant and anti-inflamma tory activity (14-19), we studied the effect of curcumin on TPA- Topical application of curcumin, the yellow pigment in turmeric and induced tumor promotion in mouse skin (20). We found that curry, strongly inhibited 12-O-tetradecanoylphorbol-13-acetate (TPA)- curcumin markedly inhibited TPA-induced tumor promotion induced ornithine decarboxylase activity, DNA synthesis, and tumor in the skin of CD-I mice previously initiated with 7,12-dimeth- promotion in mouse skin (Huang et al., Cancer Res., 48: 5941-5946, 1988). Chlorogenic acid, caffeic acid, and ferulic acid (structurally related ylbenz[a]anthracene (20). Chlorogenic acid, caffeic acid, and dietary compounds) were considerably less active. In the present study, ferulic acid were considerably weaker inhibitors of TPA-induced topical application of curcumin markedly inhibited TP A- and arachidonic tumor promotion (20). In the present report, we describe the acid-induced epidermal inflammation (ear edema) in mice, but chlorogenic effects of curcumin and its structurally related derivatives, acid, caffeic acid, and ferulic acid were only weakly active or inactive.